Shenzhenshi Ruilan Shiye Youxiangongsi – Trademark Portfolio

Entity Type: 99

Shenzhenshi Ruilan Shiye Youxiangongsi holds 1 U.S. trademark filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 1 filings in this category. Currently, 1 trademark is registered. Notable registered marks include MEDIMAMA. The owner is based in Shenzhen, Guangdong.

Room 201,Block A,No.1,Qianwan Road 1

Qianhai Shenzhen-Hong Kong coop. zone

Shenzhen, Guangdong 518000 , CN

1 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

MEDIMAMA
MEDIMAMA
Registered 2018

Trademark Classifications

Shenzhenshi Ruilan Shiye Youxiangongsi's trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (1 filing)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does Shenzhenshi Ruilan Shiye Youxiangongsi have?

Shenzhenshi Ruilan Shiye Youxiangongsi has 1 U.S. trademark filed with the USPTO. Of these, 1 registered.

What trademark classes does Shenzhenshi Ruilan Shiye Youxiangongsi file in?

Shenzhenshi Ruilan Shiye Youxiangongsi files trademarks across 1 Nice Classification class. The most active classes are Class 5 (Pharmaceuticals). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are Shenzhenshi Ruilan Shiye Youxiangongsi's most well-known trademarks?

Shenzhenshi Ruilan Shiye Youxiangongsi's registered trademark portfolio includes well-known marks such as MEDIMAMA. These are among 1 currently registered trademark in the portfolio.

What is Shenzhenshi Ruilan Shiye Youxiangongsi's trademark registration success rate?

Shenzhenshi Ruilan Shiye Youxiangongsi has a 100% trademark registration rate, with 1 out of 1 resolved applications resulting in successful registration. Currently, 0 applications are pending review.